<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fluorescein: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fluorescein: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fluorescein: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8461" href="/d/html/8461.html" rel="external">see "Fluorescein: Drug information"</a> and <a class="drug drug_patient" data-topicid="107881" href="/d/html/107881.html" rel="external">see "Fluorescein: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F172390"><span class="drugH1">Brand Names: US</span>
<ul>
<li>AK-Fluor;</li>
<li>Bio Glo;</li>
<li>Fluor-I-Strips A.T.;</li>
<li>Fluorescite;</li>
<li>Ful-Glo [DSC];</li>
<li>GloStrips</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866928"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Fluorescite;</li>
<li>Minims Fluorescein Sodium</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1014564"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Diagnostic Agent</span></li></ul></div>
<div class="block don drugH1Div" id="F53462457"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="811ce0d7-02ea-4a41-a394-ff43ada0612b">Ophthalmic angiography for retinopathy of prematurity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ophthalmic angiography for retinopathy of prematurity (ROP):</b> Limited data available: PMA â‰¥30 weeks: IV: Usual reported dose: 10 mg/kg (0.1 mL/kg of 10% solution) as a single dose followed by a saline flush; reported range: 7.7 to 10 mg/kg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18286961','lexi-content-ref-20709401','lexi-content-ref-25001158']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18286961','lexi-content-ref-20709401','lexi-content-ref-25001158'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F172404"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2b5195c9-615c-43b6-a711-c7f61d1a670f">Diagnostic staining</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic staining:</b> Limited data available: Infants, Children, and Adolescents: Ophthalmic: Strips: Moisten strip with sterile water, saline, or ophthalmic fluid. Touch conjunctiva or fornix with tip of strip until adequately stained (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="84239914-32da-4f23-a26a-37a333622147">Ophthalmic angiography</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ophthalmic angiography:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Test dose:</i> Infants, Children, and Adolescents: Intradermal: Prior to use, an intradermal test dose of 0.05 mL may be used if an allergy is suspected. Evaluate 30 to 60 minutes following intradermal injection. A negative skin test does not exclude the potential for a reaction to occur.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Diagnostic dose:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants: Limited data available: IV: Reported range: 7.7 to 10 mg/kg as a single dose followed by a saline flush (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18286961','lexi-content-ref-20709401','lexi-content-ref-25001158','lexi-content-ref-24403566']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18286961','lexi-content-ref-20709401','lexi-content-ref-25001158','lexi-content-ref-24403566'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: IV: 7.7 mg/kg (actual body weight) as a single dose into antecubital vein; maximum dose: 500 mg/dose</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51111064"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51111065"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F172392"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8461" href="/d/html/8461.html" rel="external">see "Fluorescein: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2b5195c9-615c-43b6-a711-c7f61d1a670f">Diagnostic staining</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic staining:</b> Ophthalmic: Strips: Moisten strip with sterile water, saline or ophthalmic fluid. Touch conjunctiva or fornix with tip of strip until adequately stained.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b63e7ede-fbb9-4b77-adfe-068070208140">Ophthalmic angiography/angioscopy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ophthalmic angiography/angioscopy:</b>
<b>Note:</b> Prior to injection, an intradermal test dose of 0.05 mL may be used if an allergy is suspected. Evaluate 30-60 minutes following intradermal injection. A negative skin test does not exclude the potential for a reaction to occur.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: 500 mg as a single dose into antecubital vein; a dose of 200 mg may be appropriate in cases when a highly sensitive imaging system (eg, scanning laser ophthalmoscope) is used.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral (off-label route): 1 g of injection solution has been administered orally; clarity of photographs, particularly during early arterial phase, is reportedly poorer than photographs obtained following IV administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9780101']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9780101'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990239"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987361"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustment provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F172379"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reactions associated with use of the injection. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Arterial ischemia (basilar; rare), hypotension, shock, syncope</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Convulsions (rare), dizziness (Kwan 2006), headache, nerve palsy (localized; [Kwan 2006]), seizure (rare; [Kwan 2006])</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Pruritus, rash at injection site, skin discoloration (yellow), urticaria</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Dysgeusia, gastrointestinal distress, nausea (common), vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Urine discoloration (bright yellow)</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Hemolytic anemia (Kwan 2006), sickle cell disease (Kwan 2006, Acheson 1985)</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Extravasation, inflammation at injection site</p>
<p style="text-indent:0em;">Respiratory: Bronchospasm, pulmonary edema (acute; [Kwan 2006])</p></div>
<div class="block coi drugH1Div" id="F172387"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to fluorescein or any other component of the formulation</p></div>
<div class="block war drugH1Div" id="F172377"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">â€¢ Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions may occur (death has been reported rarely); immediate treatment (including epinephrine) should be available. Serious intolerance reactions may be induced; history of adverse reaction to fluorescein or allergic reaction to foods or drugs, such as urticaria, asthma, eczema, or allergic rhinitis, may increase risk. Premedicating some patients (eg, antihistamines, corticosteroids) may be advisable. An intradermal skin test may be performed prior to use when allergy is suspected; however, a negative skin test does not rule out the potential for a reaction to occur.</p>
<p style="text-indent:-2em;margin-left:4em;">â€¢ Gastrointestinal effects: Nausea and/or vomiting and gastrointestinal distress occur commonly within the first few minutes following injection; these reactions usually subside within 10 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">â€¢ Skin/urine discoloration: Following use of the injection, skin may temporarily turn a yellow color within a few minutes of administration and usually fades in 6 to 12 hours. Urine may appear bright yellow for 24 to 36 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">â€¢ Allergies/asthma: Respiratory reactions may occur, especially in patients with a history of allergies or bronchial asthma; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">â€¢ Contact lens wearers: Ophthalmic products should not be used in patients with soft contact lenses, will cause them to discolor. Flush eyes with saline following use and wait at least 1hour prior to replacing contact lenses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">â€¢ Injection: Avoid extravasation; severe local tissue damage may result, including skin sloughing, superficial phlebitis, subcutaneous granuloma, and toxic neuritis along the median curve in the antecubital area. Following extravasation, severe pain may last up to several hours. Discontinue immediately if extravasation occurs.</p></div>
<div class="block foc drugH1Div" id="F172384"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fluorescite: 10% (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">AK-Fluor: 10% (5 mL); 25% (2 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10% (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Strip, Ophthalmic, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bio Glo: 1 mg (100 ea, 300 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fluor-I-Strips A.T.: 1 mg (300 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ful-Glo: 0.6 mg (300 ea [DSC]); 1 mg (100 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GloStrips: 1 mg (100 ea) [orange flavor]</p></div>
<div class="block geq drugH1Div" id="F172373"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16323157"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Fluorescite Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10% (per mL): $12.38</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Strip</b> (Bio Glo Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $0.26</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Strip</b> (Fluor-I-Strips A.T. Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $0.26</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Strip</b> (GloStrips Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $0.15</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866929"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fluorescite: 10% (5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25% ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2% (0.3 mL)</p></div>
<div class="block admp drugH1Div" id="F52612859"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Strips: In infants, children, and adolescents, fluorescein impregnated tip should be moistened prior to application. Strip should be applied to conjunctiva or fornix. For best results, patient should blink several times after application.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: In infants, children, and adolescents, a 23-gauge butterfly needle inserted into an antecubital vein attached to a small syringe is suggested for administration. Prior to turning off room light, steps should be taken to ensure the needle has not extravasated. Immediate treatment for anaphylaxis (including epinephrine 1 mg/mL) should be available and premedication or a test dose may be advised in some patients. Inject the dose over 5 to 10 seconds. Luminescence appears in the eye 7 to 30 seconds following injection. Maintain venous access following procedure in the event treatment is needed for anaphylaxis.</p></div>
<div class="block adm drugH1Div" id="F5095179"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Inject into the antecubital vein at a rate of ~1 mL/second using a 23-gauge butterfly needle attached to a small syringe. Prior to turning off room light, ensure extravasation has not occurred. Immediate treatment for anaphylaxis (including epinephrine) should be available or a test dose may be advised in some patients. Do not mix or dilute with other solutions or drugs; flush IV cannulas before and after drugs are administered. Luminescence usually appears in the retina and choroidal vessels in 7 to 14 seconds. Maintain venous access following procedure in the event treatment is needed for anaphylaxis.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral (off-label route): The solution for injection has been administered orally in certain patients. Four grams of sugar or 1 teaspoonful of artificial sweetener may be added to decrease the bitterness of the solution. Luminescence appears in 10 to 15 minutes following oral administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9780101']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9780101'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Strips: Fluorescein impregnated tip should be moistened prior to application. Strip should be applied to conjunctiva or fornix. For best results, patient should blink several times after application.</p></div>
<div class="block sts drugH1Div" id="F5095153"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Store at controlled room temperature; protect from freezing.</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic strips: Store at controlled room temperature.</p></div>
<div class="block usep drugH1Div" id="F53566962"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Diagnostic aid in ophthalmic angiography and angioscopy of the retina and iris vasculature (AK-Fluor: FDA approved in children and adults; Fluorescite: FDA approved in pediatric patients [age not specified] and adults)</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Staining of the anterior segment of the eye for diagnostic purposes (eg, ophthalmic procedures such as fitting contact lenses, disclosing corneal injury, and in applanation tonometry) (OTC: Bio Glo, Ful-Glo: Approved in adults)</p></div>
<div class="block cyt drugH1Div" id="F13299351"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6220438"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F5095147"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Fluorescein was found in the amniotic fluid following angiography conducted in a patient ~34 weeks' gestation (Shekleton 1980).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following fluorescein use in pregnant patients are limited (Halperin 1990; Interlandi 2021; Lin 2012; Olk 1991).</p></div>
<div class="block mopp drugH1Div" id="F53566947"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Injection: Observe for signs and symptoms of hypersensitivity reactions during procedure and after; monitor injection site</p></div>
<div class="block pha drugH1Div" id="F172376"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Fluorescein sodium, a fluoresce dye, responds to wavelengths between 465-490 nm of electromagnetic radiation and light, and fluoresces at wavelengths of 520-530 nm.</p></div>
<div class="block phk drugH1Div" id="F15405175"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 0.5 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Rapidly metabolized to fluorescein monoglucuronide (~80% is metabolized 1 hour following IV administration)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine; systemic clearance essentially complete 48 to 72 hours after dose</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F172388"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Fluorescein</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Angiofluor | Fluoresceina | Fluorescite | Rfg-kit</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Fluorescein natrium | Fluorescite</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Fluorescein novartis | Fluoresoft | Minims fluorescein</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ak-fluor | Fluoresceine | Fluoresceine Chauvin Benelux | Fluorescine | Minims fluorescein sodium</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Fluorescein | Fluorescite</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Fludiag | Fluoresceina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Fluorescite</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">BioGlo | Fluoresceina | Fluorescina sodica</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Fluocyne</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Fluorescein alcon | Fluoreszein | Fluosine</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Fluoresceina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Fluocyne | Fluorescein Se Thilo</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Fluorescein | Sunnyfloresin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Colircusi Fluoresceina | Fluoresceina oculos | Minims fluoresceina sodica</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Minims fluorescein</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Fluocyne | Fluoresceine faure | Fluorexon</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Anatera | Fluor amps | Mf fluorescein | Retinofluor</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Fluocyne</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Fluorescite | Minims fluorescein</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Fluorescein | Fluorescite</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Fluorescein</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Fluresin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Fluoralfa | Fluoresceina</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Florestin | Fluorescein kobayashi | Fluorescein sodium kobayashi | Fluorescite</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Fluorecein nvr | Fluorescein | Fluorescite</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Fluorescite | Minims fluorescein sodium</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Fluorescite</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Fluoresceine Chauvin Benelux</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Fluoresceine | Fluorescite | Minims fluorescein</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Fluoresceine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Fluoresceina</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Fluorescite</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Fluoresceinedinatrium</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Fluoresceine ciba | Fluoresceine natrium akorn | Fluoresceinnatr | Fluoresceinnatrium | Fluoresceinnatrium minims | Fluorescite</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Fluorescein</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Ak-fluor | Aka fluor | Fluorescite</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Fluoroscein</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ak-fluor | Fluocyne | Fluoresceine | Fluoresceine serb | Fluoresceine Thea | Fluorescite</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ak-fluor | Fluorescite</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Fluoresceina | Minims fluorescein sodium</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Fluorescite | Minims Fluorescein Sodium</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Fluorescein | Fluorescein novartis | Fluorescite | Flurenat</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Minims fluorescein sodium</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Fluoresceinnatrium chauvin | Fluorescite</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Fluorescite</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Fluorescite</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Fluocyne</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Fluorescein | Fluorescite | Fluoreszein | Flusible</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Fluorescein | Fluorescite</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Fluorescite</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Fluoresceina | Fluorescite</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Fluorescein | Fluorescite | Minims fluorescein sodium</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-AK-Fluor.1">
<a name="AK-Fluor.1"></a>AK-Fluor (fluorescein injection 10% and 25%) injection [prescribing information]. Gurnee, IL: Akorn Operating Company LLC; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18286961">
<a name="18286961"></a>Azad R, Chandra P, Khan MA, Darswal A. Role of intravenous fluorescein angiography in early detection and regression of retinopathy of prematurity. <i>J Pediatr Ophthalmol Strabismus</i>. 2008;45(1):36-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorescein-pediatric-drug-information/abstract-text/18286961/pubmed" id="18286961" target="_blank">18286961</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  BIOGLO strip (flourescein) [prescribing information]. Rancho Cucamonga, CA: HUB Pharmaceuticals, LLC; April 2012.</div>
</li>
<li>
<div class="reference">
                  Fluorescein GloStrips [prescribing information]. St. Louis, MO: Nomax Inc; February 2017.</div>
</li>
<li>
<div class="reference">
                  Fluorescite (fluorescein injection 10%) [prescribing information]. Fort Worth, Texas: Alcon Laboratories Inc; November 2021.</div>
</li>
<li>
<div class="reference">
                  Fluorets ophthalmic strips (flourescein) [prescribing information]. Rochester, NY: Bausch &amp; Lomb Inc; October 2009</div>
</li>
<li>
<div class="reference">
                  Ful-Glo ophthalmic strips (flourescein) [prescribing information]. Lake Forest, IL: Akorn Inc; March 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1970705">
<a name="1970705"></a>Halperin LS, Olk RJ, Soubrane G, Coscas G. Safety of fluorescein angiography during pregnancy. <i>Am J Ophthalmol</i>. 1990;109(5):563-566.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorescein-pediatric-drug-information/abstract-text/1970705/pubmed" id="1970705" target="_blank">1970705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9780101">
<a name="9780101"></a>Hara T, Inami M, and Hara T. Efficacy and Safety of Fluorescein Angiography With Orally Administered Sodium Fluorescein. <i>Am J Ophthalmol</i>. 1998;126(4):560-564.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorescein-pediatric-drug-information/abstract-text/9780101/pubmed" id="9780101" target="_blank">9780101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34636695">
<a name="34636695"></a>Interlandi E, Pellegrini F, Silvestrin C, Pece A, Pavesio C. Hellp syndrome-related hypertensive chorioretinopathy: A multimodal imaging and optical coherence tomography angiography (OCTA) study. <i>Eur J Ophthalmol</i>. 2021:11206721211051238. doi:10.1177/11206721211051238<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorescein-pediatric-drug-information/abstract-text/34636695/pubmed" id="34636695" target="_blank">34636695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Saunders Elsevier; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16451256">
<a name="16451256"></a>Kwan AS, Barry C, McAllister IL, et al. Fluorescein Angiography and Adverse Drug Reactions Revisited: The Lions Eye Experience. <i>Clin Experiment Ophthalmol</i>. 2006;34(1):33-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorescein-pediatric-drug-information/abstract-text/16451256/pubmed" id="16451256" target="_blank">16451256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20709401">
<a name="20709401"></a>Lepore D, Molle F, Pagliara MM. Atlas of fluorescein angiographic findings in eyes undergoing laser for retinopathy of prematurity. <i>Ophthalmology</i>. 2011;118(1):168-175.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorescein-pediatric-drug-information/abstract-text/20709401/pubmed" id="20709401" target="_blank">20709401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25001158">
<a name="25001158"></a>Lepore D, Quinn GE, Molle F, et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. <i>Ophthalmology</i>. 2014;121(11):2212-2219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorescein-pediatric-drug-information/abstract-text/25001158/pubmed" id="25001158" target="_blank">25001158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22869028">
<a name="22869028"></a>Lin P, Hahn P, Fekrat S. Peripheral retinal vascular leakage demonstrated by ultra-widefield fluorescein angiography in preeclampsia with HELLP syndrome. <i>Retina</i>. 2012;32(8):1689-90. doi:10.1097/IAE.0b013e318261a757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorescein-pediatric-drug-information/abstract-text/22869028/pubmed" id="22869028" target="_blank">22869028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3369981">
<a name="3369981"></a>Maquire AM, Bennett J. Fluorescein elimination in human breast milk. <i>Arch Ophthalmol</i>. 1988;106(6):718-719.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorescein-pediatric-drug-information/abstract-text/3369981/pubmed" id="3369981" target="_blank">3369981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2333925">
<a name="2333925"></a>Mattern J, Mayer PR. Excretion of fluorescein into breast milk. <i>Am J Ophthalmol</i>. 1990;109(5):598-599.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorescein-pediatric-drug-information/abstract-text/2333925/pubmed" id="2333925" target="_blank">2333925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1821200">
<a name="1821200"></a>Olk RJ, Halperin LS, Soubrane G, Coscas G. Fluorescein angiography--is it safe to use in a pregnant patient? <i>Eur J Ophthalmol</i>. 1991;1(2):103-106.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorescein-pediatric-drug-information/abstract-text/1821200/pubmed" id="1821200" target="_blank">1821200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7426506">
<a name="7426506"></a>Shekleton P, Fidler J, Grimwade J. A case of benign intracranial hypertension in pregnancy. <i>Br J Obstet Gynaecol</i>. 1980;87(4):345-347. doi:10.1111/j.1471-0528.1980.tb04554.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorescein-pediatric-drug-information/abstract-text/7426506/pubmed" id="7426506" target="_blank">7426506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24403566">
<a name="24403566"></a>Tahija SG, Hersetyati R, Lam GC, Kusaka S, McMenamin PG. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. <i>Br J Ophthalmol</i>. 2014;98(4):507-512.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluorescein-pediatric-drug-information/abstract-text/24403566/pubmed" id="24403566" target="_blank">24403566</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 105145 Version 122.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
